BTA administration in patients with BM across the three cancers
| BC | NSCLC | PC | ||
| N | 295 | 117 | 121 | |
| Total unique agents | Median | 1.0 | 1.0 | 1.0 |
| Min–max | 1.0–3.0 | 1.0–2.0 | 1.0–1.0 | |
| Denosumab administrations | N | 56 (19.1%) | 12 (10.3%) | 0 (0.0%) |
| Only received once | 11 | <6 | – | |
| Median | 6.50 | 2.0 | – | |
| Min–max | 1.0–61.0 | 1.0–14.0 | – | |
| Zoledronic acid administrations | N | 229 (77.9%) | 93 (79.5%) | 113 (93.4%) |
| Only received once | 32 | 52 | 51 | |
| Median | 9.0 | 1.0 | 2.0 | |
| Min–max | 1.0–50.0 | 1.0–21.0 | 1.0–34.0 |
The remaining %s that add up to the total 100% in the table include BTAs other than denosumab or zoledronic acid.
.BC, breast cancer; BTA, bone-targeting agent; NSCLC, non-small cell lung cancer; PC, prostate cancer.